Cormorant Asset Management »

Neurogene shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Neurogene (NGNE) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Neurogene

Tip: Access up to 7 years of quarterly data

All positions including Neurogene held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neurogene by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $15M 746k 19.38

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Ambrx Biopharma
Eyepoint Pharmaceuticals Com New (EYPT)
Bridgebio Pharma (BBIO)
Arcellx Common Stock (ACLX)
Rayzebio
Biomea Fusion (BMEA)
Immunovant (IMVT)
Alpine Immune Sciences (ALPN)
Pharvaris N V (PHVS)
Alx Oncology Hldgs (ALXO)
Tarsus Pharmaceuticals (TARS)
Cymabay Therapeutics
Vaxcyte (PCVX)
Crinetics Pharmaceuticals In (CRNX)

View all positions for Cormorant Asset Management

Top funds holding Neurogene

EcoR1 Capital
Samsara BioCapital
Dr. Jeffrey R. Jay, M.D.
Redmile Group
Henderson Group
Cormorant Asset Management
Arrowpoint Asset Management
Casdin Capital
Avidity Partners Management
Baker Bros. Advisors
Walleye Trading Advisors
Susquehanna International
Nantahala Capital Management
Vanguard Group
Bank of America Corporation

View all funds holding Neurogene